Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
Pediatric Studies Characteristics - Detail
FDA Home
Pediatrics
Pediatric Studies Characteristics
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Approval Date:
07/23/2009
Trade Name:
Actonel
Generic or Proper Name (*):
risedronate
Indications Studied:
Osteogenesis imperfecta
Therapeutic Category:
Bone density
Ages Studied:
4-<16 years
Study #:
2
Study Type:
Efficacy/Safety
Study Design:
Single-Blind/Placebo/Parallel Group
No Patients:
143
No Centers:
20
No Countries:
5
BPCA(B), PREA(P):
B
Asian:
4
Black:
0
Other:
8
White:
118
Native Hawaiian or Pacific Islander:
0
American Indian/Alaska Native:
0
Hispanic/Latino:
13
Non-Hispanic/Non Latino:
0
-
-